PD-1/PD-L1 and CTLA-4 are the most widely used targets for HCC in immunotherapy, mainly focusing on PD-1/PD-L1 mono-antibodies, which have become world-class “stars”. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.